Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Sarnath Chattaraj"'
Publikováno v:
Journal of Diabetes Science and Technology. 17:302-313
Introduction: Automated insulin delivery (AID) has become a well-known research topic devoted to achieving better glycemic outcomes. AID systems consist primarily of three components: the continuous glucose monitoring system, the insulin delivery sys
Autor:
Ron Brazg, Satish K. Garg, Anuj Bhargava, James R. Thrasher, Kashif Latif, Bruce W. Bode, Timothy S. Bailey, Barry S. Horowitz, Arvind Cavale, Yogish C. Kudva, Kevin B. Kaiserman, George Grunberger, John Chip Reed, Sarnath Chattaraj, Gina Zhang, John Shin, Vivian Chen, Scott W. Lee, Toni L. Cordero, Andrew S. Rhinehart, Robert A. Vigersky, Bruce A. Buckingham
Publikováno v:
Diabetes Technology & Therapeutics. 24:535-543
Publikováno v:
Journal of diabetes science and technology.
Continuous subcutaneous insulin infusion (CSII, or insulin pump) and continuous glucose monitoring (CGM) sensors have been increasingly used and associated with improved glycemic control by people with type 1 diabetes and insulin-requiring type 2 dia
Publikováno v:
Diabetes. 71
Objective: The wear duration of insulin infusion sets (IIS) is impacted by initial local trauma caused by cannula insertion and sustained inflammation due mostly to insulin infusion, both of which affect insulin absorption. Efforts have been made to
Publikováno v:
Diabetes. 71
Objective: Medtronic Mio™ 30 infusion set (M30IS) is a single-use consumable for pump users with pre-loaded inserter, utilizing a 30° insertion angle, and labeled for 3-day use. The M30IS wear duration is impacted by initial local trauma caused by
Autor:
Kevin T. Nguyen, Nicole Y. Xu, Bruce A. Buckingham, Sarnath Chattaraj, Ohad Cohen, Lutz Heinemann, John Pickup, Jannet Svensson, Robert A. Vigersky, Jenise C. Wong, Ralph Ziegler
Publikováno v:
Journal of diabetes science and technology, vol 16, iss 3
J Diabetes Sci Technol
J Diabetes Sci Technol
Continuous subcutaneous insulin infusion (CSII) therapy is becoming increasingly popular. CSII provides convenient insulin delivery, precise dosing, easy adjustments for physical activity, stress, or illness, and integration with continuous glucose m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65fe295d6ade6f4950575b5ae8874aea
https://escholarship.org/uc/item/1cx1m7xn
https://escholarship.org/uc/item/1cx1m7xn
Autor:
Gina Zhang, Barry Horowitz, Ronald L. Brazg, Anuj Bhargava, Satish K. Garg, Yogish C. Kudva, Suiying Huang, Robert Vigersky, Arvind Cavale, George Grunberger, Timothy S. Bailey, Sarnath Chattaraj, Bruce A. Buckingham, John Shin, Vivian Chen, Kevin B Kaiserman, James Thrasher
Publikováno v:
Diabetes. 70
Objective: Most insulin infusion sets (ISs) are labeled for 2- or 3-days use. The Medtronic EWIS is designed to increase wear time up to 7 days. This study reports on EWIS survival and performance during the pivotal trial (ClinicalTrials.gov: NCT0411
Publikováno v:
Diabetes. 70
Objective: A combination insulin infusion and glucose-sensing device will dramatically improve the ease of use for automated insulin delivery systems. The objective of this preclinical study was to collect safety and efficacy data during 7-day wear o
Autor:
Vivian Chen, Kevin B Kaiserman, James Thrasher, Anuj Bhargava, Suiying Huang, Barry Horowitz, Bruce A. Buckingham, John Shin, George Grunberger, Gina Zhang, Satish K. Garg, Ronald L. Brazg, Timothy S. Bailey, Arvind Cavale, Robert Vigersky, Sarnath Chattaraj, Yogish C. Kudva
Publikováno v:
Diabetes. 70
Objective: Most insulin infusion sets (ISs) are labeled for 2- or 3-days use. The Medtronic EWIS is designed to increase wear time up to 7 days, and demonstrated a 74.8% survival rate (77.8%, excluding inadvertent early removal) in the pivotal trial
Autor:
Ohad Cohen, Jannet Svensson, Kirsten Nørgaard, Sarnath Chattaraj, Lutz Heinemann, David C. Klonoff, Matthias Heschel, Bruce A. Buckingham, Jennifer Y Zhang, Robert A. Vigersky, Trisha Shang
Publikováno v:
J Diabetes Sci Technol
Continuous subcutaneous insulin infusion (CSII) is becoming increasingly used for achieving target glycemic control as well as providing flexibility in lifestyle. In a widely used version of CSII, the insulin pump itself is attached to one end of an